Остеопороз и сахарный диабет: современный взгляд на проблему

Взаимосвязь сахарного диабета (СД) с нарушениями костного метаболизма на сегодняшний день до конца не понята. В то время, как СД 1 типа (СД1) характеризуется снижением показателей минеральной плотности костей (МПК), при СД 2 типа (СД2) в ряде исследований снижения МПК не отмечается или имеются более высокие показатели по срав- нению с контролем. В то же время при СД2, как и при СД1 имеется высокий риск переломов, что указывает на ухудшениекачества? кости при диабете. В настоящей статье рассматриваются различные механизмы повреждения костной ткани при СД, а также возможные причины различий в тяжести костных нарушений при СД1 и СД2. Учитывая высокий риск переломов костей стоп у пациентов с СД, отдельное внимание уделено дистальной нейропатии как возможному фактору, ухудшающему состояние костной ткани.

остеопороз, сахарный диабет, дистальная диабетическая полинейропатия

1. Hamilton EJ, Rakic V, Davis WA, Chubb SA, Kamber N, Prince RL, Davis TM. Prevalence and predictors of osteope- nia and osteoporosis in adults with type 1 diabetes. Diabet Med. 2009 Jan;26(1):45–52. DOI: 10.1111/j.1464- 5491.2008.02608.x.

2. Mastrandrea LD, Wactawski-Wende J, Donahue RP, Hovey KM, Clark A, Quattrin T. Young women with type 1 diabetes have lower bone mineral density that persists over time. Diabetes Care. 2008 Sep;31(9):1729–1735. DOI: 10.2337/dc07- 2426.

3. Tuominen JT, Impivaara O, Puukka P, Ronnemaa T. Bone mineral density in patients with type 1 and type 2 diabetes. Diabetes Care. 1999 Jul;22(7):1196–1200.

4. Yamaguchi T, Kanazawa I, Yamamoto M, Kurioka S, Yamauchi M, Yano S, Sugimoto T. Associations between components of the metabolic syndrome versus bone mineral density and vertebral fractures in patients with type 2 diabetes. Bone. 2009 Aug;45(2):174–179. DOI: 10.1016/j.bone.2009.05.003.

5. Yaturu S, Humphrey S, Landry C, Jain SK. Decreased bone mineral density in men with metabolic syndrome alone and with type 2 diabetes. Med Sci Monit. 2009 Jan;15(1):CR5-9.

6. Valerio G, del Puente A, Esposito-del Puente A, Buono P, Mozzillo E, Franzese A. The lumbar bone mineral density is af- fected by long-term poor metabolic control in adolescents with type 1 diabetes mellitus. Horm Res. 2002;58(6):266–272.

7. Nicodemus KK, Folsom AR; Iowa Women's Health Study. Type 1 and type 2 diabetes and incident hip fractures in postmeno- pausal women. Diabetes Care. 2001 Jul;24(7):1192–1197.

8. Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, Jamal SA, Black DM, Cummings SR; Study of Os- teoporotic Features Research Group. Older women with diabe- tes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab. 2001 Jan;86(1):32–38.

9. Lipscombe LL, Jamal SA, Booth GL, Hawker GA. The Risk of Hip Fractures in Older Individuals With Diabetes: A populationbased study. Diabetes Care. 2007 Apr;30(4):835–841.

10. Hirano Y, Kishimoto H, Hagino H, Teshima R: The change of bone mineral density in secondary osteoporosis and vertebral fracture incidence. J Bone Miner Metab. 1999;17(2):119–124.

11. Melton LJ 3rd, Leibson CL, Achenbach SJ, Therneau TM, Khosla S. Fracture risk in type 2 diabetes: update of a populationbased study. J Bone Miner Res. 2008 Aug;23(8):1334–1342. DOI: 10.1359/jbmr.080323.

12. Schwartz AV, Margolis KL, Sellmeyer DE, Vittinghoff E, Ambrosius WT, Bonds DE, Josse RG, Schnall AM, Simmons DL, Hue TF, Palermo L, Hamilton BP, Green JB, Atkinson HH, O'Connor PJ, Force RW, Bauer DC. Intensive glycemic control is not associated with fractures or falls in the ACCORD randomized trial. Diabetes Care. 2012 Jul;35(7):1525–1531. DOI: 10.2337/ dc11-2184.

13. Campos Pastor MM, Lopez-Ibarra PJ, Escobar-Jimenez F, Serrano Pardo MD, Garcia-Cervigon AG. Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study. Osteoporos Int. 2000;11(5):455–459.

14. Wang W, Zhang X, Zheng J, Yang J. High glucose stimulates adipogenic and inhibits osteogenic differentiation in MG-63 cells through cAMP/protein kinase A/extracellular signal-regulated kinase pathway. Mol Cell Biochem. 2010 May;338(1–2):115–122. DOI: 10.1007/s11010-009- 0344-6.

15. Kayal RA, Tsatsas D, Bauer MA, Allen B, Al-Sebaei MO, Kakar S, Leone CW, Morgan EF, Gerstenfeld LC, Einhorn TA, Graves DT. Diminished bone formation during diabetic fracture healing is related to the premature resorption of cartilage associated with increased osteoclast activity. J Bone Miner Res. 2007 Apr;22(4):560–568.

16. Botolin S, Faugere MC, Malluche H, Orth M, Meyer R, Mc- Cabe LR. Increased bone adiposity and peroxisomal proliferator-activated receptor-γ2 expression in type I diabetic mice. Endocrinology. 2005 Aug;146(8):3622–3631.

17. Kang L, Chen Q, Wang L, Gao L, Meng K, Chen J, Ferro A, Xu B. Decreased mobilization of endothelial progenitor cells contributes to impaired neovascularization in diabetes. Clin Exp Pharmacol Physiol. 2009 Oct;36(10):e47–56. DOI: 10.1111/j.1440–1681.2009.05219.x.

18. Saito M, Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int. 2010 Feb;21(2):195–214. DOI: 10.1007/s00198-009-1066-z.

19. Silva MJ, Brodt MD, Lynch MA, McKenzie JA, Tanouye KM, Nyman JS, Wang X. Type 1 diabetes in young rats leads to progressive trabecular bone loss, cessation of cortical bone growth, and diminished whole bone strength and fatigue life. Bone Miner Res. 2009 Sep;24(9):1618–27. DOI: 10.1359/ jbmr.090316.

20. Saito M, Fujii K, Mori Y, Marumo K. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int. 2006 Oct;17(10):1514–1523.

21. Eller-Vainicher С, Zhukouskaya VV, Tolkachev YV, Koritko SS, Cairoli E, Grossi E, Beck-Peccoz P, Chiodini L, Shepelkevich AP. Low Bone Mineral Density and Its Predictors in Type 1 Diabetic Patients Evaluated by the Classic Statistics and Artificial Neural Network Analysis. Diabetes Care. 2011 Oct;34(10):2186– 2191. DOI: 10.2337/dc11-0764.

22. Haffner SM, Bauer RL. The association of obesity and glucose and insulin concentrations with bone density in premenopausal and postmenopausal women. Metabolism. 1993 Jun;42(6):735–758.

23. Adami S. Bone health in diabetes: considerations for clinical management. Curr Med Res Opin. 2009 May;25(5):1057– 1072. DOI: 0.1185/03007990902801147.

24. Yang J, Zhang X, Wang W, Liu J. Insulin stimulates osteoblast proliferation and differentiation through ERK and PI3K in MG-63 cells. Cell Biochem Funct. 2010 Jun;28(4):334–341. DOI: 10.1002/cbf.1668.

25. Gunczler P, Lanes R, Paoli M, Martinis R, Villaroel O, Weisinger JR. Decreased bone mineral density and bone formation markers shortly after diagnosis of clinical type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2001 May;14(5):525–528.

26. Elefteriou F. Regulation of bone remodeling by the central and peripheral nervous system. Arch Biochem Biophys. 2008 May 15;473(2):231–236. DOI: 10.1016/j.abb.2008.03.016.

27. Nuntapornsak A, Wongdee K, Thongbunchoo J, Krishnamra N, Charoenphandhu N. Changes in the mRNA expression of osteoblast-related genes in response to beta(3)-adrenergic agonist in UMR106 cells. Cell Biochem Funct.28:45– Cell Biochem Funct. 2010 Jan;28(1):45–51. DOI: 10.1002/cbf.1617.

28. Shi Y, Yadav VK, Suda N, Liu XS, Guo XE, Myers MG Jr, Karsenty G. Dissociation of the neuronal regulation of bone mass and energy metabolism by leptin in vivo. Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20529–20533. DOI: 10.1073/pnas.0808701106.

29. Kakoki M, Sullivan KA, Backus C, Hayes JM, Oh SS, Hua K, Gasim AM, Tomita H, Grant R, Nossov SB, Kim HS, Jennette JC, Feldman EL, Smithies O. Lack of both bradykinin B1 and B2 receptors enhances nephropathy, neuropathy, and bone mineral loss in Akita diabetic mice. Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10190–10195. DOI: 10.1073/ pnas.1005144107.

30. Zhang R, Naughton DP. Vitamin D in health and disease: Current perspectives. Nutr J. 2010 Dec 8;9:65. DOI: 10.1186/1475-2891-9-65.

31. An ZM, Huang MJ, Zhang M, Xiong ZY, Guo D. Relationship of 25(OH)VD with bone mass and other indicators in male patients with diabetes mellitus. Sichuan Da Xue Xue Bao Yi Xue Ban. 2009 Jan;40(1):52–54.

32. Svoren BM, Volkening LK, Wood JR, Laffel LM. Significant vitamin D deficiency in youth with type 1 diabetes mellitus. J Pediatr. 2009 Jan;154(1):132–134. DOI: 10.1016/j. jpeds.2008.07.015.

33. Devaraj S, Yun JM, Duncan-Staley CR, Jialal I. Low vitamin D levels correlate with the proinflammatory state in type 1 diabetic subjects with and without microvascular complications. Am J Clin Pathol. 2011 Mar;135(3):429–433. DOI: 10.1309/ AJCPJGZQX42BIAXL.

34. Di Cesar DJ, Ploutz-Snyder R, Weinstock RS, Moses AM. Vitamin D deficiency is more common in type 2 than in type 1 diabetes. Diabetes Care. 2006 Jan;29(1):174.

35. Ivers RQ, Cumming RG, Mitchell P, Peduto AJ; Blue Mountains Eye Study. Diabetes and risk of fracture: the Blue Mountains Eye Study. Diabetes Care. 2001 Jul;24(7):1198–1203.

36. Wallace C, Reiber GE, LeMaster J, Smith DG, Sullivan K, Hayes S, Vath C. Incidence of falls, risk factors for falls, and fallrelated fractures in individuals with diabetes and a prior foot ulcer. Diabetes Care. 2002 Nov;25(11):1983–1986.

37. Vestergaard P, Rejnmark L, Mosekilde L. Diabetes and its complications and their relationship with risk of fractures in type 1 and type 2 diabetes. Calcif Tissue Int. 2009 Jan;84(1):45–55. DOI: 10.1007/s00223-008-9195-5. Epub 2008 Dec 9.

38. Patel S, Hyer S, Tweed K, Kerry S, Allan K, Rodin A, Barron J. Risk factors for fractures and falls in older women with type 2 diabetes mellitus. Calcif Tissue Int. 2008 Feb;82(2):87–91. DOI: 10.1007/s00223-007-9082-5.

39. Kim JH, Jung MH, Lee JM, Son HS, Cha BY, Chang SA. Dia- betic peripheral neuropathy is highly associated with non- traumatic fractures in Korean patients with type 2 diabetes mellitus. Clin Endocrinol (Oxf). 2012 Jul;77(1):51–55. DOI: 10.1111/j.1365-2265.2011.04222.x.

40. Rix M, Andreassen H, Eskildsen P. Impact of peripheral neuropathy on bone density in patients with type 1 diabetes. Diabetes Care. 1999 May;22(5):827–831.

41. Forst T, Pfutzner A, Kann P, Schehler B, Lobmann R, Schafer H, Andreas J, Bockisch A, Beyer J. Peripheral osteopenia in adult patients with insulin-dependent diabetes mellitus. Diabet Med. 1995 Oct;12(10):874–879.

42. Strotmeyer ES, Cauley JA, Schwartz AV, de Rekeneire N, Resnick HE, Zmuda JM, Shorr RI, Tylavsky FA, Vinik AI, Harris TB, Newman AB. Reduced peripheral nerve function is related to lower hip BMD and calcaneal QUS in older white and black adults: the Health, Aging, and Body Composition Study. J Bone Miner Res. 2006 Nov;21(11):1803–1810.

43. Young MJ, Marshall A, Adams JE, Selby PL, Boulton AJ. Osteopenia, neurological dysfunction, and the development of Charcot neuroarthropathy. Diabetes Care. 1995 Jan;18(1):34–38.

44. Vignery A, McCarthy TL. The neuropeptide calcitonin gene-related peptide stimulates insulin-like growth factor I production by primary fetal rat osteoblasts. Bone. 1996 Apr;18(4):331–335.

45. Akopian A, Demulder A, Ouriaghli F, Corazza F, Fondu P, Bergmann P. Effects of CGRP on human osteoclast-like cell formation: a possible connection with the bone loss in neurological disorders? Peptides. 2000 Apr;21(4):559–564.

46. Yiang Y, Nyengaard JD, Zhang JS, Jakobsen J. Selective loss of calcitonin gene-related peptide-expressing primary sensory neurons of the a-cell phenotype in early and experimental diabetes. Diabetes. 2004 Oct;53(10):2669–2675.

47. La Fontaine J, Harkless LB, Sylvia VL, Carnes D, Heim-Hall J, Jude E. Levels of endothelial nitric oxide synthase and calcitinin gene-related peptide in the Charcot foot: a pilot study. J Foot Ankle Surg. 2008 Sep–Oct;47(5):424–429. DOI: 10.1053/j. jfas.2008.05.009.

48. Gopalakrishnan V, Vignesh RC, Arunakaran J, Aruldhas MM, Srinivasan N. Effects of glucose and its modulation by insulin and estradiol on BMSC differentiation into osteoblastic lineages. Biochem Cell Biol. 2006 Feb;84(1):93–101.

49. Cai L, Okumu FW, Cleland JL, Beresini M, Hogue D, Lin Z, Filva- roff EH. A slow release formulation of insulin as a treatment for os- teoarthritis. Osteoarthritis Cartilage. 2002 Sep;10(9):692–706.

50. Molinuevo MS, Schurman L, McCarthy AD, Cortizo AM, To- losa MJ, Gangoiti MV, Arnol V, Sedlinsky C. Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies. J Bone Miner Res. 2010 Feb;25(2):211–221. DOI: 10.1359/jbmr.090732.

51. Ma P, Gu B, Ma J, E L, Wu X, Cao J, Liu H. Glimepiride induces proliferation and differentiation of rat osteoblasts via the PI3- kinase/Akt pathway. Metabolism. 2010 Mar;59(3):359–366. DOI: 10.1016/j.metabol.2009.08.003.

52. Debiais F. Thiazolidinediones: antidiabetic agents with effects on bone. Joint Bone Spine. 2009 May;76(3):221–223. DOI: 10.1016/j.jbspin.2009.01.005.

53. Viboolvorakul S, Niimi H, Wongeak-in N, Eksakulkla S, Patumraj S. Increased capillary vascularity in the femur of aged rats by exercise training. Microvasc Res. 2009 Dec;78(3):459–463. DOI: 10.1016/j.mvr.2009.07.003.

54. Maggio AB, Rizzoli RR, Marchand LM, Ferrari S, Beghetti M, Farpour-Lambert NJ. Physical activity increases bone mineral density in children with type 1 diabetes. Med Sci Sports Exerc. 2012 Jul;44(7):1206–1211. DOI: 10.1249/MSS.0b013e3182496a25.

55. Russo CR. The effects of exercise on bone. Basic concepts and implications for the prevention of fractures. Clin Cases Miner Bone Metab. 2009 Sep;6(3):223–228.

56. Brown SA, Sharpless JL. Osteoporosis: an under-appreciated complication of diabetes. Clin. Diabetes. 2004; (22):10–20.

57. Elder G. Pathophysiology and recent advances in the management of renal osteodystrophy. J Bone Miner Res. 2002 Dec;17(12):2094–2105.

58. Richard JL, Almasri M, Schuldiner S. Treatment of acute Charcot foot with bisphosphonates: a systematic review of the literature. Diabetologia. 2012 May;55(5):1258–1264. DOI: 10.1007/ s00125-012-2507-3.